Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.
Megan Coylewright, MD, MPH
Advertisement
Articles by Megan Coylewright, MD, MPH
Advertisement
Latest Updated Articles
- Coverage With Evidence Development: Where Are We Now?
April 7th 2022
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
AHRQ Grant Freeze Halts Patient Safety Research Nationwide
3
FDA Advisory Panel Votes Against Approval of Deramiocel for DMD
4
MASLD, MASH Linked to Higher Mild Cognitive Impairment Risk, Lower Dementia Odds
5